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Summary 
The cytotoxic and cytokinetic effects of ICRF-159 and its d-enantiomer ICRF-187 have been examined in 
vitro. The effects of both agents were identical. Cytotoxicity is dependent on both the drug concentration 
and the duration of  drug exposure. Drug exposure for twice the cell cycle time is necessary for maximum 
effect. Cytotoxicity is also dependent upon the rate of  cell proliferation. A rapidly growing cell population 
is more sensitive to brief drug exposure than a slowly growing population. 
The cytokinetic effects were studied using flow cytometry, determination of [3 H]-thymidine incorporation 
and mitotic index. ICRF-159/187 appears to act only during the Gz phase of  the cell cycle. There is no detec- 
table delay in cell passage through the G1/S  boundary or in transit through S phase. Inhibition of  DNA syn- 
thesis occurs only after the G2 block prevents subsequent entry of cells in S phase. A fraction of the cells, 
depending upon drug concentration, undergo further DNA synthesis without cell division, resulting in a tetra- 
poid cell population. 
The cytokinetic effects were determined in the bone marrow of patients receiving ICRF-187. All dose-rates 
produced G2/M accumulation in the marrow with depletion of S phase cells. One patient was given a single 
injection of  1.0 gm/M z . G2/M accumulation was observed 24 h after treatment, with recovery to a pretreat- 
ment DNA cycle distribution 24 h later. 
These studies suggest that a continuous drug infusion, or intermittent infusions timed to allow the normal 
cell population to recover, may produce superior clinical activity with this agent. A Phase I study of such 
an intermittent schedule is indicated. 
Introduction 
ICRF-159 (razoxane), an EDTA derivative devel- 
oped at the Imperial Cancer Research Fund, has 
shown antineoplastic activity in animal tumor mod- 
els (1) as well as in clinical studies (2). A synergistic 
antineoplastic effect has been demonstrated in 
animal tumor models for combinations of ICRF- 
159 plus irradiation, adriamycin, 5-fluorouracil, 
cisplatinum, cyclophosphamide, or hexamethylme- 
lamine (3-6) .  Methotrexate resistant L5187Y cells 
are more sensitive to ICRF-159 than a methotrexate 
sensitive line (7). 
Previous studies of the cellular effect of  ICRF- 
159 have produced somewhat conflicting results. 
Studies by Hellman and co-workers have suggested 
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a site of action in the G2 phase of the cell cycle with 
production of G2 arrest (8-10). Other investigators 
have demonstrated inhibition of RNA, protein and 
DNA synthesis and have suggested that ICRF-159 
acts as an alkylating agent (11). G2 arrest can be a 
non-specific effect of cell treatment with a number 
of antineoplastic agents with different mechanisms 
of action. Arrest in the G2 phase has been demon- 
strated with alkylating agents, antitumor antibio- 
tics, and protein synthesis inhibitors (12-14). 
Adriamycin has been shown to produce G2 arrest in 
vitro and cell recovery with subsequent progression 
through the cell cycle occurs only after brief expo- 
sure to low drug concentrations (15). Exposure to 
high drug concentrations or long exposure times 
result in irreversible arrest. Bleomycin, on the other 
hand, produces a G2 block that is reversible, and 
release of the block results in a synchronized cell 
population (16). This action of bleomycin has been 
demonstrated in human tumors in vivo (17) and has 
been successfully incorporated into clinical treat- 
ment regimens (18). Tobey has shown that various 
agents stop progression in different points in the G2 
phase and has suggested that the G2 phase may con- 
tain a surveillance mechanism for DNA damage 
(19). Demonstration of G2 arrest, therefore, does 
not automatically imply a G2 phase specific site of 
action. 
ICRF-159 is a racemic mixture. Because of poor 
water solubility, clinical trials were conducted with 
an oral formulation. However, recognition of vari- 
able bioavailability led to isolation and formulation 
of the more soluble d-enantomier ICRF-187 (20, 
21). This parenteral agent has completed Phase I 
trials and is currently undergoing Phase II testing. 
This study was undertaken to further define the 
cytokinetic effects of ICRF-187, compare the in 
vitro effects of ICRF- 159 and ICRF- 187, determine 
the cytotoxic and cytokinetic effects of variation in 
drug concentration and exposure time, and assess 
the cytokinetic effect of ICRF- 187 on the bone mar- 
row of patients entered into Phase II trials utilizing 
continuous infusion, daily x 3 and daily x 5 treat- 
ment schedules. 
Materials and methods 
Burkitt lymphoma cells (P3 J) were maintained in 
continuous culture at 37~ in RPMI-1640 medium 
containing 10% fetal bovine serum, penicillin 100 
t~g/ml and streptomycin 100 #g/ml. Cells in the log 
phase of growth for 24 h were diluted with fresh 
culture medium to a concentration of 2.5-3.0 x 105 
cells/ml just prior to each experiment. At this initial 
cell concentration, untreated cultures remained in 
the log phase of growth for 36 h with a doubling 
time of 13-15 h. After 72 h of growth, the cultures 
reached a growth plateau at a density of 2.2 _+ .2 
x 106 cells/ml. Cell viability determined by ery- 
throcin B dye exclusion, was in excess of 95% at the 
cell densities used in these experiments. 
The small cell lung cancer line NC1-H69C, ob- 
tained from Dr. John Minna, The National Cancer 
Institute, was maintained in RPMI-1640 containing 
15% fetal calf serum with penicillin and streptomy- 
cin. Cells in the log phase of growth have a 
doubling time of 40-44 h and maintain a dye exclu- 
sion viability in excess of 85%. 
ICRF-159 (preservative-free, furnished by the 
National Cancer Institute) was dissolved in 0.1 N 
HC1 immediately prior to use. ICRF-187, also ob- 
tained from the National Cancer Institute, was dis~ 
solved in distilled water. Cytotoxicity was deter- 
mined using a soft agar colony-forming assay. At 
indicated times aliquots were removed from repli- 
cate control and drug treated cultures, centrifuged 
then resuspended in medium containing 15% fetal 
bovine serum and 0.3% agar. One ml, containing 
5 x 10 cells was pipetted over 1.0 ml base layers con- 
taining 0.5% agar in 35 mm Petri dishes. The 
number of colonies per plate (> 30 cells/colony) 
were hand counted, using an inverted microscope, 
5-7 days after plating. Percent survival was calcu- 
lated as the number of colonies/plate for the drug 
treated cultures divided by the number of colonies/ 
plate for the controls. Cloning efficiency averaged 
50 + 5% for the untreated P3J cultures, and 10 + 
2% for H69C. Each cloning assay was i~erformed 
in triplicate. Each experiment was repeated at least 
once for both agents. 
Thymidine incorporation was measured after the 
cultures were incubated with [3 H]-thymidine (Me- 
thyl-3H-thymidine, 20 Ci/mM, New England 
Nuclear, Boston, Mass), 0.5 /zCi/ml, for 30 min. 
The cells were immediately centrifuged and washed 
with 2 volumes of iced 0.9% NaC1. The nucleic acid 
was precipitated by addition of 4 ml iced 5~ per- 
chloric acid, and the sample was centrifuged. After 
two further washes with iced perchloric acid, the 
pellet was resuspended in 1 ml 5% perchloric acid 
and incubated at 90~ for 30 min. [3 H]-thymidine 
content of the supernatant was determined by li- 
quid scintillation counting in a Packard Tricarb 
Scintillation Counter and the DNA content was 
assayed by the diphenylamine method of Burton 
(22). 
Mitotic index was determined by counting the 
number of mitoses/1000 cells using Wright-stained 
preparations. Cell counts were done with a Model 
F Coulter Counter. 
Flow cytometry was performed using a Coulter 
TPS-1 Cell Sorter. Cells were prepared for fluoro- 
metric analysis of DNA content by incubation for 
10 min in 0.05 mg/ml propidium iodine in 0.1~ so- 
dium citrate buffer at 0~ (23). 1.2-2.0 x 104 cells 
were analyzed per sample at a peak channel setting 
at 104 cells. 
Patient samples 
Approval of this investigation was obtained from 
the University of Michigan Committee to Review 
Grants from Clinical Research and Investigation 
Involving Human Beings. Written informed con- 
sent was obtained from all participating subjects. 
Bone marrow aspirates were obtained from the 
posterior iliac crest using a Jamshidi needle. Two to 
3 ml samples were withdrawn, anticoagulated with 
EDTA and divided into two aliquots for analysis by 
flow cytometry. The mononuclear cell fraction was 
separated by centrifugation in a Ficol/Hypaque 
gradient (Histopaque-1077, Sigma Chemical Co., 
St. Louis, Mo.), and stained with propidium 
iodide. The bone marrow sample cell count was 
determined on a Model F Coulter Counter after 
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Fig. l. The effects of  drug concentration and exposure duration 
on ICRF-187 cytotoxicity. P3 J cells were exposed to ICRF-187 
at the concentrations shown. At the indicated times aliquots 
were removed and cell kill was determined by the soft agar 
cloning assay. 
O ,  1 izg/ml;  9  3/zg/ml;  II ,  10 #g/ml .  
Results 
The experiments using P3 J cells shown in Figs. 1, 4, 
8 and 9 were performed using ICRF-159 and 
ICRF-187. The cytotoxic and cytokinetic effects 
observed were identical for both agents. Dissolving 
ICRF-187 in 0.1 N HC1 did not alter the drug effect. 
Therefore the results obtained with either agent 
have been used interchangeably. 
The effects of a timed exposure to 1 /xg/ml, 3 
/zg/ml or 10/~g/ml of ICRF-187 is shown in Fig. 1. 
A 28-h exposure to 10/zg/ml was required for maxi- 
mum cytotoxicity. A drug concentration of 40 
izg/ml produced the same effect as is shown for 10 
~g/ml. The cytotoxicity of 3 and 10 ~g/ml was the 
same for exposure times of 12 h or less. Exposure 
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Fig. 2. The effect of cell proliferation rate on ICRF-159 cytotoxicity. 
P3 J cells at the initial cell densities shown, were incubated with 20 
/~g/ml ICRF-159 for 14 h (stippled'bars) or 21 h (hashed bar). 
city than the 10/zg/ml drug concentration. By thirty 
hours, the cloning efficiency in cultures exposed to 
3/~g/ml began to increase as the cells recovered from 
drug exposure, or possibly as cells resistant to this 
concentration continued to proliferate. 
Some of  the cytotoxicity difference between 10 
/~g/ml and 1 /~g/ml could result from drug break- 
down with loss of effect at the lower concentration. 
Cells were therefore exposed to these two drug con- 
centrations for a total of 24 h, however, every 8 h the 
cultures were centrifuged and resuspended in fresh, 
drug-containing medium. Renewing the drug con- 
centration every 8 h increased the cytotoxicity of 1 
/~g/ml from 51 _+ 2% to 30 + 4O/o colony survival. 
This suggests that drug breakdown may have occur- 
red during a single 24-h exposure. The cytotoxicity 
produced by 10/~g/ml was not increased by drug 
replacement. Under both exposure conditions the 
cytotoxicity of 10/~g/ml was 5 _+ 2% colony sur: 
vival. Thus, sufficient drug apparently remained 
after a single addition of  10/~g/ml to maintain the 
cytotoxic effects. 
These results demonstrate that maximum cell kill 
is achieved by a continuous drug exposure. How- 
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Fig. 3. Comparison of exposure time dependent cytotoxicity of 
ICRF-187 in P3 J and H69C cells. Cultures were incubated with 20 
/~g/ml ICRF-187, and aliqnots were removed for soft agar cloning 
assay at the times indicated. Medium and drug was replaced at 24 h 
in the H69C cultures. 
Q ,  P3J; O ,  H69C. 
ever, with a phase specific agent, a given duration 
of  drug exposure should produce greater cell kill in 
cells with a short cycle time. The effect of  Burkitt 
cell proliferation rate on ICRF-159 cytotoxicity is 
shown in Fig. 2. The doubling time of  untreated log 
phase P3J cultures was 13-15 h, and during a 14-h 
incubation period, the viable cell count of un- 
treated cultures with an initial cell concentration of 
0.25~ 106 cell/ml increased 107%0, compared to a 
53% increase with an initial inoculum of 0.75 x 106 
cells/ml and 19% increase with an initial inoculum 
of 1.5 • 106 cells/ml. Cultures with an initial con- 
centration of 0.75 x 106 cells/ml doubled in cell 
count after 19-20 h of  growth. The cytotoxic ef- 
fects of  a 14-h exposure to 20 #g/ml ICRF-159 de- 
creased as the initial cell inoculum increased, how- 
ever, when the drug exposure time was extended to 
21 h to encompass the longer doubling time of  cul- 
tures plated at 0.75 x 106 cells/ml, the cytotoxicity 
produced was equal to that observed with the faster 
growing cell population. Since the cell cultures with 
higher cell counts were at a lower initial pH (7.0 
compared to 7.4 + 0.1), the effect of  culture pH on 
the cytotoxicity of  ICRF-159 was also investigated. 
Variation in pH from 6.9 to 7.9 had no effect on the 
cytotoxicity of  a 12-h exposure to 20 #g/ml.  
Similar results are seen when two cell lines with 
different cycle times are compared.  Figure 3 shows 
the effect of  a 20 #g/ml  exposure on the Burkitt 
cells, and on a small cell lung cancer line NC1-H69C 
which has a log phase doubling time of  40 h. Twen- 
ty /zg/ml  produced maximum cytotoxicity in both 
cell lines. For all durations of  exposure there is a 
preferential killing of  the Burkitt line. 
In the clinical treatment of  solid tumors,  sensitive 
normal tissues, particularly the bone marrow in the 
case of  ICRF-187, would be represented by the 
more rapidly proliferating cells. An intermittant 
drug administration which allowed normal tissue 
recovery would be a potential alternative to con- 
tinuous drug administration. This alternative was 
examined in vitro. Burkitt cells were exposed to 20 
/zg/ml of  ICRF-187 for 8 h (a concentration • time 
exposure that produced 50% cell kill), centrifuged, 
then resuspended in either drug containing medium 
for an additional 8 h, or drug-free medium. Ali- 
quots of  cells incubated in the drug-free medium 
were removed at 4-h intervals, then re-exposed to 
ICRF-187 for a second 8-h duration and cytotoxici- 
ty assayed. As shown in Fig. 4, an 8-h drug ex- 
posure reduced cell survival 50%, and a 16-h con- 
tinuous exposure produced 80% cell kill. As the 
drug-free incubation was lengthened f rom 4 to 20 h, 
the cell population gradually recovered f rom the in- 
itial drug effect. With a 12- to 16-h delay between 
the two drug exposures, cytotoxicity was equal to a 
single 8-h exposure. 
The same drug exposure conditions were used 
with the H69C cell line except that a 20-h exposure 
time was used. Twenty hours was selected to pro- 
duce a 50% cell kill. The results are also displayed 
in Fig. 4. The time to recovery f rom the first drug 
exposure is only slightly delayed compared to the 
more rapidly proliferating P3 J cell line. This sug- 
gests that recovery f rom drug-induced damage is 
not cycle time dependent, and is not a result of  cell 
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Fig. 4. Time course of recovery from an initial drug exposure. 
P3 J cells were exposed to 20/zg/ml ICRF- 187 for 8 h then placed 
in drug-free medium for 0 to 24 h prior to a second 8-h exposure. 
H69C cells were exposed to 20/zg/ml for 20 h during each drug 
incubation. Cytotoxicity was determined following the second 
drug exposure. 
9 PHJ; 9 H69C; O,  a single drug exposure: 8 h for P~J, 20 
h for H69C. 
The cytokinetic effect of  ICRF-159 
The effect of  20 #g/ml  of  ICRF-159 on thymidine 
uptake, mitotic index, and DNA content per cell are 
shown in Fig. 5. The mitotic index began to fall be- 
tween 60 and 90 min of drug exposure; however, 
thymidine incorporation was not affected until ex- 
posure time exceeded 4 h. There was a progressive 
increase in the DNA content per cell. For compari-  
son, the effects of  nitrogen mustard (0.5 #g/ml) and 
colchicine (1.0 #g/ml)  on thymidine incorporation 
and DNA content per cell are shown in Fig. 6. This 
was the lowest nitrogen mustard concentration that 
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Fig. 5. The cytokinetic effects of ICRF- 159 in P3 J cells. Simulta- 
neous control and drug treated cells (20/tg/ml) were assayed for 
mitotic index, thymidine incorporation and cell content of DNA. 
Percent of control was calculated by dividing the results from the 
drug treated cultues by the results from concomitant controls. 
9 cell content of DNA;  9  thymidine incorporation; [], 
mitotic index. 
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Fig. 6. The cytokinetic effects of colchicine and nitrogen mustard 
in P3 J cells. 
O,,cell content of DNA, colchicine; 9 cell content of DNA, 
rf]trogen mustard; [~, thymidine incorporation, colchicine; i ,  
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Fig. 7. Changes in mitotic index and thymidine incorporation 
following exposure to ICRF-159. P3 J cells were incubated with 
20/zg/ml jCRF-159 for 14 h, then placed in drug-free medium. 
Aliquots were removed at the times indicated for determination 
of mitotic index and thymidine incorporation. 
9 thymidine incorporation; O, mitotic index. 
(da ta  not  shown).  The effect  o f  colchicine on 
thymid ine  i nco rpo ra t i on  and  cell content  o f  D N A  
was qui te  s imilar  to  tha t  o f  ICRF-159.  In cont ras t ,  
n i t rogen mus t a rd  caused a more  rap id  d rop  in 
thymid ine  i nc o rpo ra t i on  wi thout  increase in D N A  
conten t  per  cell. 
To  invest igate  the poten t ia l  use o f  ICRF-159  as a 
synchroniz ing  agent ,  thymid ine  i nco rpo ra t i on  and 
mi to t ic  index were s tudied fol lowing drug remova l  
(Fig. 7). A peak  in mi to t ic  accumula t ion  occur red  4 
to  8 h fo l lowing remova l  o f  ICRF-159.  A peak  in 
D N A  synthesis was seen 8 to 12 h fo l lowing drug  
removal .  These results show tha t  fol lowing 
ICRF-159 exposure ,  cells move  th rough  the subse- 
quent  division cycle in a par t i a l ly  synchronized  
wave. 
The  effect  o f  a con t inuous  exposure  o f  ICRF-187 
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Fig. 8. Changes in cell cycle distribution during a continuous exposure to ICRF-187. P3 J cells were incubated with ICRF-187 at the 
concentrations shown. Aliquots were removed for flow cytometry at the indicated times. 
on cell cycle distribution was determined by flow 
cytometry. As shown in Fig. 8, the two higher drug 
concentrations rsulted in maximum cell accumula- 
tion with a G2 DNA content, whereas 1 #g/ml pro- 
duced a partial effect. There was no inhibition of 
cell progression through the G1/S boundary or 
through the DNA synthetic phase. There was, how- 
ever, an accumulation of  cells with an 8N DNA 
content suggesting that a portion of  the cells were 
capable of  subsequent DNA synthesis, but that 
cytokinesis was prevented. This effect was most 
pronounced at the 5 ~g/ml drug concentration. 
To further evaluate the possible use of  the 
ICRF-159 as a synchronizing agent, cells were ex- 
posed to 20 ~g/ml and 5 ~g/ml for 14 h, then resus- 
pended in a drug-free medium. Flow cytometry was 
performed at sequential time points thereafter. 
Figure 9 shows the results of this experiment. After 
removal from the drug-containing medium, the 
cells proceeded through G~ into S in a partially syn- 
chronized wave. 
To investigate the potential relationship of  these 
in vitro data to clinical therapy, the cytokinetic ef- 
fects of ICRF-187 on the bone marrow of  patients 
receiving the agent were determined. Figure 10 
shows sequential cytofluorographs on a patient 
who received 1.5 gm/M 2 ICRF-187 for three suc- 
cessive days. The baseline marrow shows a stan- 
dard pretherapy DNA distribution pattern. Twen- 
ty-four hours after the first dose G2/M accumula- 
tion and S phase depletion is evident. Twenty-four 
hours following the second dose, G2/M accumula- 
tion persists with some cells in the 4 N - 8 N  range. 
Cells with a 4 N - 8 N  DNA content are still evident 
24 h after the third dose. Seventy-two hours after 
the third dose few S or G2/M cells remain in the 
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Fig. 9. Changes in cell cycle distribution following exposure to ICRF-187. P3J cells were exposed to 5 or 20 #g/ml  ICRF-187 for 14 
h, the n placed in drug-free medium. Aliquots were removed for flow cytometry at the times indicated. 
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Fig. 10. Effect of  ICRF-187 on the bone marrow cell cycle distribution during a daily • 3 treatment course. Bone marrow samples were 
obtained at the times indicated and processed for flow cytometry. Arrows signify ICRF-187 administration. 
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Fig. 12. Changes in bone marrow cell cycle distribution follow- 
ing a single dose of  ICRF-187. 
marrow. The cytokinetic effects of a 48-h con- 
tinuous infusion are shown in Fig. 11. The effects 
are almost identical to the results seen in the 
previous patient with G2/M accumulation, 4 N -  8N 
cells and few S, G z / M  cells at 120 h. Identical DNA 
distribution patterns were seen in two patients who 
received 1.25 gm/M / ICRF-187 daily for five con- 
secutive days and in one additional patient at both 
the continuous infusion and daily x 3 dose rates. 
To assess the time to recovery from a single dose 
of  ICRF-187, one patient was given an injection of  
1.0 gm/M z . As shown in Fig. 12, G z / M  accumula- 
tion is evident 24 h after the dose. Twenty-four 
hours later the bone marrow has regained a pre- 
therapy DNA distribution. 
Discussion 
The cytotoxicity of  ICRF-159/187 is clearly related 
to both drug concentration and duration of ex- 
posure. There is minimal inhibitory effect with ex- 
posure times less than one-half the cycle time, even 
with high drug concentrations. Maximum drug ef- 
fect requires an exposure time at least twice the cell 
cycle time. Hellman & Field (9) found similar re- 
sults using H Ep /2  cells assayed by the colony form- 
ing technique and suggested that the agent must act 
in a brief portion of the cell cycle. Hallowes et al. 
(8) found exposure-time dependent variation in 
ICRF-159 cytotoxicity in three different cell lines. 
In contrast to our findings, the agent had no effect 
on cell proliferation during the initial 24-h ex- 
posure, but produced progressive cell-kill during a 
subsequent 48-h incubation. 
Part  of the difference in cytotoxicity observed in 
vitro for various drug concentrations is due to dis- 
appearance of  the active compound from the 
medium with a consequent decrease in the duration 
of  exposure. Dawson has shown that the break- 
down of  ICRF-159 is a pH-dependent hydrolysis 
(24). The half-life of the drug is approximately 12 
h at pH 7.0. Replacing a 1 t~g/ml concentration with 
fresh drug every 8 h significantly increased the cyto- 
toxicity. Clear concentration differences remain 
however, as evidenced by the fact that the addition 
of fresh drug at a concentration of  1/~g/ml every 8 
h for 24 h produces less cytotoxicity than an iden- 
tical 24-h exposure to 10 #g/ml. Since the peak 
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plasma level achieved in man following a 3 gm/M 2 
dose is less than 5/~g/ml (25), the duration of drug 
exposure becomes crucial for attaining an antineo- 
plastic effect. Creaven et al. (26) have shown that 
the bone marrow suppression that occurs with the 
clinical use of ICRF-159 is highly schedule-depen- 
dent. Part of the schedule dependency, however, 
may be due to poor oral absorption of high doses 
with decreased bioavailability (20). 
The magnitude of observed drug effect is also 
greatly dependent upon cell proliferation. As 
shown by the experiments illustrated in Figs. 2 and 
3, slowly growing cell populations are less sensitive 
to an equal concentration • time exposure than 
'rapidly growing cells. Equal cytotoxicity can be 
achieved when exposure time is increased. This pro- 
liferation dependence has been demonstrated in 
other in vivo and in vitro systems (8, 27, 28). This 
suggests that the slowly growing tumors encounter- 
ed clinically could be effectively treated only by a 
long duration of drug exposure. 
Our studies support the contention that ICRF- 
159/187 is a phase specific agent having a site of ac- 
tion in G2 phase of the cycle (8-10, 27, 28). Figures 
5 and 8 show that ICRF-159 produces a Gz arrest 
in treated cells with a gradual accumulation of cells 
in this phase of the cell cycle. The mitotic index 
begins to decline within 60 to 90 min of drug addi- 
tion (Fig. 5). Since the duration of Gz in this cell 
line is 1.5 h, the site of action must be in the Gz 
phase in order to produce this rapid drop in mitotic 
index. If the drug produces an immediate effect 
when added to the cell cultures, then the site of ac- 
tivity would be in early Gz (19). However, Dawson 
has shown that ICRF-159 enters cells slowly by dif- 
fusion, and maximum intracellular concentration is 
not attained for 2 to 3 h (24). Therefore, the as- 
sumption of immediate action may not be warrant- 
ed, and the drug effect may be occurring later ~ in 
Gz. Others have reported an increase in mitotic in- 
dex or the percent of prophase cells with ICRF-159 
exposure (10, 29). We did not observe an increase 
in mitotic index, and the mitotic cells present were 
not arrested in prophase. 
Following the G2 arrest, a fraction of the cells 
move into DNA synthesis without cell division. 
This is best demonstrated in the flow cytometric 
analysis illustrated in Fig. 8. These cells are again 
arrested in a second G2 peak with an 8N DNA con- 
tent. Other investigators have observed a progres- 
sive increase in cell size and an increase in tetraploid 
cells (8, 30). Since the majority of cells remain ar- 
rested in the initial G2 block, the subpopulation of 
cells that proceed into a second synthetic phase are 
presumably more resistant to the drug effect. 
Taylor & Bleehen (31) demonstrated that EMT6 
cells resistant to ICRF-159 are polyploid with twice 
the usual DNA content and chromosome numbers. 
Hallowes et al. (8) have observed that dead cells as 
defined by dye exclusion are mononuclear. The 
demonstration in Fig. 8 of a greater percentage of 
tetraploid cells with a 5/zg/ml suggests that these 
cells that achieve tetraploidy are partially drug 
resistant. In order to kill these cells, the drug must 
be present throughout the second G2 phase and this 
explains why a drug exposure of twice the cycle time 
is necessary for maximum cytotoxicity. In contrast 
to the stable polyploidy noted by Taylor & Bleehan, 
the cultures that recovered from drug treatment in 
our experiments were made up of cells with normal 
DNA content. The exposure time used in our ex- 
periments, however, may not have been sufficient 
to produce a stable resistant cell population. 
The flow cytometry and thymidine incorporation 
studies do not show any delay of progression 
through the G1/S boundary or in S phase transit. 
DNA synthesis inhibition has been previously re- 
ported (11). However, we observe decreased DNA 
synthesis only after the arrest in G2 progression has 
depleted the cell pool entering G1 and S. This is in 
contrast to an equally cytotoxic concentration of 
nitrogen mustard which produces a rapid inhibition 
of thymidine incorporation, and similar to the ef- 
fect seen with colchicine (Fig. 6). We were unable 
to detect any increase in thymidine incorporation as 
reported by Creighton & Birnie (11) and by Grieder 
et al. (29). In the latter instance, the thymidine up- 
take was corrected by the cell count. Since the 
ICRF-159 produces a rapid decrease in cells passing 
through mitosis while leaving a S phase undisturb- 
ed, an artificial increase in thymidine incorporation 
would be detected. Hallowes et al. (8) also found no 
effect on the labelling index during the initial phase 
of drug exposure. 
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There are clear cytokinetic differences between 
ICRF-159/187 and other compounds which pro- 
duce G2/M arrest in vitro. The alkylating agents, 
with nitrogen mustard as the prototype, are not 
phase specific, produce DNA synthesis inhibition at 
a high concentration, and slow or inhibit transit 
throughout the cell cycle (12, 32). Adriamycin pro- 
duces a G2 block that correlates with cytotoxicity 
(13). However, at high drug concentration, transit 
throughout the cell cycle is inhibited (15), and S 
phase cells are most sensitive to the cytotoxic effect 
(33). Mithramycin and bleomycin produce primari- 
ly G2 arrest but inhibit DNA synthesis at high con- 
centrations (16, 34-36). Protein synthesis in- 
hibitors such as puromycin delay transit through 
the G1/S boundary in addition to producing G2 ar- 
rest (14). Colchicine and the periwinkle analogues 
vincristine and vinblastine produce metaphase ar- 
rest, whereas ICRF-159 exposure results in a fall in 
mitotic index. 
As further contrast between the alkylating 
agents, antitumor antibiotics and ICRF-159, Daw- 
son was unable to demonstrate covalent binding of 
ICRF-159 to DNA, or any physical interaction be- 
tween ICRF-159 and intracellular macromolecules 
(24). Also, Sharpe et al. could find no visible 
evidence of chromosome damage following ICRF- 
159 exposure (10). 
Any conclusions concerning the mechanism of 
action of ICRF-159/187 must remain highly specu- 
lative. As Tobey has summarized, completion of 
mitosis requires two discrete periods of protein syn- 
thesis just prior to mitosis (37). The mRNA neces- 
sary for synthesis of these proteins is transcribed 
early in Ga. ICRF-159/187 could interfere with the 
early G2 events or could inhibit synthesis of the pro- 
teins necessary for initiation of mitosis (38). The 
cytokinetic effects of ICRF-159/187 may also result 
in part from inhibition of microfilament synthesis 
or function. Gosalvey et al. (39) have shown that 
ICRF-159 will inhibit the capping of surface immu- 
noglobulins, a process dependent upon microfila- 
ments. This inhibition occurs at low drug concen- 
trations and may result from chelation of ferric 
iron. Cytochalasin B, an inhibitor of microfilament 
formation, also produces multinucleated cells (31). 
With ICRF-159/187 additional mechanisms must 
be active since nuclear division is also inhibited in 
the majority of cells. 
The studies also have implications for clinical 
therapy with ICRF-159/187. It is clear from Fig. 2 
that the drug must be present for at least twice the 
cell cycle time to produce maximum cell kill. This 
suggests that a continuous infusion should be more 
effective than intermittent bolus treatment. How- 
ever, human tumors in general have considerably 
longer cell cycle durations than most normal cell 
populations, and excessive toxicity could result 
from prolonged infusions. Intermittent drug infu- 
sions, with drug-free intervals timed to allow re- 
covery of the normal cells with a short cycle time, 
may produce a selective cytotoxicity to a slowly 
growing cell population. 
The cytokinetic analysis of the bone marrows of 
patients receiving ICRF-187 reveal the same effects 
that were observed in vitro. Proliferating cells are 
initially blocked in G2/M. A fraction of the cells 
continue in cycle without cell division and accumu- 
late with an 8N DNA content. A 48-h continuous 
infusion, and daily 3- or 5-day injections produce 
marked depletion of the S and GE/M compart- 
ments consistent with the subsequent myelosup- 
pression that developed in these patients. The one 
patient who received a single injection of ICRF-187 
had cytokinetic recovery of the bone marrow 48 h 
following the dose. Based on these observations, a 
Phase I study of intermittent ICRF-187 with injec- 
tions timed to allow bone marrow recovery is indi- 
cated. 
ICRF-159/187 also has some potential for use as 
a synchronizing agent in a combination drug regi- 
men. ICRF-159/187 treatment could be followed 
after an appropriate interval by an S phase specific 
agent to take advantage of the partial cell cycle syn- 
chrony demonstrated in Fig. 7 and 9. An alternative 
approach would be to administer the S phase speci- 
fic agent at the end of an ICRF-159 infusion timed 
to produce bone marrow arrest in GE. A tumor cell 
population, having a longer cell cycle time should 
not have achieved S phase cell depletion during this 
short infusion period. These potential clinical ap- 
plications will require further investigation in 
animal tumor models. 
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